In a preclinical mouse model of melanoma, anti-PD1 immunotherapy triggered changes in both tumor-infiltrating and circulating T cell subsets, with a marked increase in EM and CM CD8+ T cells associated with durable responses (38). Here, CD8A is linked to melanoma.